Transaminase elevation on placebo during phase I trials: prevalence and significance.
about
Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not usefulLucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjectsLiver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric SettingsA systematic review of agomelatine-induced liver injuryA live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers.A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working groupWhat can we learn from clinical trials of anticonvulsant drugs in epilepsy?Designing and interpreting the results of first-time-to-man studies.Acetaminophen safety and hepatotoxicity--where do we go from here?Answers to the most common questions about the hepatic safety profile of duloxetine.Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trialsSerum transaminase levels should be measured immediately prior to dosing in early phase I clinical trials.Macitentan: entry-into-humans study with a new endothelin receptor antagonist.A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical TrialsCharacterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit.Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor.
P2860
Q26995810-AE057D19-63F9-4CBD-BFC2-32ADA84AB1A4Q28468569-3A949CB3-7309-4D4E-B8AA-5BBFE94EB5EFQ28552027-AF7E5D99-99FD-4B83-9BB0-C3C026567ADDQ28648515-18C17BEA-C90F-4FA8-AE5F-1E90CC5BD8FDQ30377443-1E19D1FF-7E15-4020-AC45-80C452BC2D25Q30794443-8DE0CD20-6DE5-4E72-862F-6039295B27F4Q33681753-32287616-3F36-4FCE-8C4A-57F8952FACE6Q34182924-E30A575B-F997-412B-A416-C6ED42E4C920Q34381371-D6B61534-4E13-4B05-A6B1-B0F04FF0444EQ34558531-507A5333-E4F9-47E6-B27D-961CFD377E37Q35236261-1839B217-DA4C-4C9C-A040-AB4D900887EBQ36905831-37074655-BE42-4400-9895-3921DF47EF16Q37226413-85ED83A7-C99E-4B1D-9231-C7B59577E4E6Q37321425-4510CF7B-9C28-420A-BD7A-7B9818EC532DQ37699723-EA943AE5-2618-4E33-9564-61118654B104Q37721681-7769CD92-67A1-4E19-9BF4-21393A1A6799Q38362243-E49C578F-463E-4E18-B916-4F01AA9B8911Q38683174-8B679344-F971-41CD-8F3B-AA2835075F18Q38876395-A74AD843-38C3-4E9E-A723-33E1B5AAF476Q40031389-20AE19F7-6D83-490F-BD19-BF0ABE39EC9AQ42284189-6E5940CE-A01D-4D97-9C05-1FCF38AB152DQ43172644-3E513015-B4D8-447C-8670-2F9B28B80C0BQ47895451-E00C94D2-A5E0-416E-B9E5-2BE9DAE3A679Q51371365-565EA199-77BD-46E2-B66C-7E2BF81A9021
P2860
Transaminase elevation on placebo during phase I trials: prevalence and significance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@ast
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@en
type
label
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@ast
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@en
prefLabel
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@ast
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@en
P2093
P1476
Transaminase elevation on placebo during phase I trials: prevalence and significance.
@en
P2093
P2860
P356
10.1046/J.1365-2125.1999.00952.X
P407
P577
1999-07-01T00:00:00Z